Pharmaceutical Patent Due Diligence in M&A: The Definitive Analyst’s Guide to IP Valuation, Risk Quantification, and Deal Architecture
Part I: The Strategic Logic of Patent Due Diligence Why Pharma IP Is the Business, Not Just an Asset In
May 2025
Patent Box Tax Strategy for Pharma: The Complete IP & Investment Playbook
Every blockbuster drug carries two distinct asset classes: the molecule itself and the legal monopoly wrapped around it. The Patent
Patent Box Tax Strategy for Pharma: The Complete IP & Investment Playbook Read Post »
The Forecasts That Missed by Billions: A 2026 Playbook for Predicting Drug Market Potential
In 2023, Goldman Sachs put the ceiling on the global anti-obesity drug market at $100 billion by 2030 [1]. By
Exploring the Role of South Africa in the Global Pharmaceutical Landscape
Strategic Analysis of the South African Pharmaceutical Landscape The South African pharmaceutical market is the primary industrial and regulatory anchor
Exploring the Role of South Africa in the Global Pharmaceutical Landscape Read Post »
The DTC Telehealth Reset: What Hims & Hers’ 2026 Reckoning Means for the Next Wave of Patent-Cliff Disruptors
Hims & Hers Health posted a net loss of $86.3 million in the second quarter of 2026, on revenue of
Drug Patents as Revenue Forecasts: The Pharma Analyst’s Complete Guide to IP-Based Sales Modeling and IP Valuation
Introduction: The Patent Filing Is a Financial Document The global prescription drug market cleared $1.6 trillion in annual revenue by
